INDICATIONS AND USAGE（适应症）

RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

DOSAGE（服用剂量）

The recommended oral dose of RINVOQ is 15 mg once daily with or without food.

RINVOQ may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

ADVERSE REACTIONS（不良反应）

Serious Infections

Malignancy

Thrombosis

Gastrointestinal Perforations

Laboratory Parameters

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/2966aec7-2ef0-923c-d8ff-fe1a957bf095/spl-doc?hl=upadacitinib

Upanibinformation